A Double Blind, Randomised, Dose Finding, Repeat Dose, Phase II, Multicentre Study of Alpharadin for the Treatment of Patients With Hormone Refractory Prostate Cancer and Skeletal Metastases

Trial Profile

A Double Blind, Randomised, Dose Finding, Repeat Dose, Phase II, Multicentre Study of Alpharadin for the Treatment of Patients With Hormone Refractory Prostate Cancer and Skeletal Metastases

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Dec 2014

At a glance

  • Drugs Radium 223 chloride (Primary)
  • Indications Bone metastases; Prostate cancer
  • Focus Therapeutic Use
  • Sponsors Bayer
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 07 Jun 2011 Results presented at the 47th Annual Meeting of the American Society of Clinical Oncology.
    • 19 Feb 2011 Results were presented in combination with results from the BC1-02 study (59651) at the 2011 Genitourinary Cancers Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top